EBV-associated B-cell LPDs
| Infectious mononucleosis |
| Posttransplant and other iatrogenic B-cell LPDs |
| Monomorphic, polymorphic, plasmacytic, or HL-like variants |
| Lymphomatoid granulomatosis |
| EBV+ DLBCL associated with chronic inflammation |
| Fibrin-associated DLBCL |
| Pyothorax-associated lymphoma |
| EBV+ mucocutaneous ulcer |
| Hodgkin’s lymphoma |
| Subset of classic and HIV-associated |
| Mainly mixed cellularity and lymphocyte depleted |
| Primary effusion lymphoma (HHV-8 and EBV) |
| Germinotropic B-LPD (HHV-8 and EBV) |
| Plasmablastic lymphoma |
| Primary CNS lymphoma |
| Immunocompromised patients (e.g. HIV) |
| EBV+ DLBCL, NOS |
| Burkitt lymphoma |
| All endemic and a subset of sporadic and HIV associated |
| Infectious mononucleosis |
| Posttransplant and other iatrogenic B-cell LPDs |
| Monomorphic, polymorphic, plasmacytic, or HL-like variants |
| Lymphomatoid granulomatosis |
| EBV+ DLBCL associated with chronic inflammation |
| Fibrin-associated DLBCL |
| Pyothorax-associated lymphoma |
| EBV+ mucocutaneous ulcer |
| Hodgkin’s lymphoma |
| Subset of classic and HIV-associated |
| Mainly mixed cellularity and lymphocyte depleted |
| Primary effusion lymphoma (HHV-8 and EBV) |
| Germinotropic B-LPD (HHV-8 and EBV) |
| Plasmablastic lymphoma |
| Primary CNS lymphoma |
| Immunocompromised patients (e.g. HIV) |
| EBV+ DLBCL, NOS |
| Burkitt lymphoma |
| All endemic and a subset of sporadic and HIV associated |
HL, Hodgkin lymphoma; HHV-8, human herpesvirus 8; NOS, not otherwise specified.